100 Participants NeededMy employer runs this trial

Rozanolixizumab for Myasthenia Gravis

(MyVisionXT Trial)

Recruiting at 6 trial locations
UC
Overseen ByUCB Cares
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: UCB Biopharma SRL
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of the study is to assess the long-term safety and efficacy of rozanolixizumab in adult study participants with ocular myasthenia gravis.

Are You a Good Fit for This Trial?

This trial is for adults with ocular myasthenia gravis who have already received at least one dose of rozanolixizumab or placebo in a previous study. Participants must be able to follow the study schedule and, if female and able to become pregnant, agree to use contraception.

Inclusion Criteria

Participant for whom the investigator considers a favorable benefit/risk for participation
I am male or female.
I am at least 18 years old.
See 4 more

Exclusion Criteria

Participant meets any of the withdrawal criteria defined in MG0038
I plan to get a live vaccine during or soon after the study treatment.
I have taken medications that suppress my immune system or certain biologic therapies.
See 2 more

What Are the Treatments Tested in This Trial?

Interventions

  • Rozanolixizumab

Trial Overview

The study is testing the long-term safety and effectiveness of rozanolixizumab in people with ocular myasthenia gravis. All participants will receive this medication over an extended period.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: RozanolixizumabExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

UCB Biopharma SRL

Lead Sponsor

Trials
118
Recruited
23,200+

Jean-Christophe Tellier

UCB Biopharma SRL

Chief Executive Officer since 2015

MD from University of Reims Champagne-Ardenne, Rheumatology specialization from University of Paris V, Executive business programs at Harvard and INSEAD

Dr. Iris Loew-Friedrich

UCB Biopharma SRL

Chief Medical Officer since 2014

MD from University of Leuven, PhD in Medical Sciences from University of Leuven